A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
GLP-1 receptor agonists (GLP-1 RAs) lower glucose and reduce cardiovascular events in type 2 diabetes, with noted renal benefits. Few studies directly compare GLP-1 RAs. This study aims to compare the effects of semaglutide and dulaglutide on renal f…
BACKGROUND: Managing severe obesity in youth with chronic, progressive conditions, such as juvenile Huntington disease, presents unique challenges. Juvenile Huntington disease, is characterized by rapid neurodegeneration, with most patients experienc…
The precise mechanism of action of semaglutide in obese patients remains uncertain, although it is evident that the drug confers a significant cardiac benefit. An excessively high-fat diet has been demonstrated to result in an increased expression of…
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text].
IMPORTANCE: Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neu…
Semaglutide is a glucagon-like-peptide-1 receptor agonist (GLP-1 RA) that is approved for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Common adverse drug reactions (ADR) of semaglutide include nausea, vomiting, abdominal pain, const…
BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight re…
BACKGROUND AND OBJECTIVES: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to treat obesity and diabetes. Semaglutide, a GLP-1RA, is linked to nonarteritic ischemic optic neuropathy (NAION), macular edema, and retinopathy.…
IMPORTANCE: The efficacy and safety of oral semaglutide, 50 mg, in an East Asian population that also includes individuals with type 2 diabetes (T2D), who are prone to weight-related complications at lower body mass index (BMI; calculated as weight i…
AIMS: This study evaluated the metabolic efficacy of ForePass-a novel, incision-free, reversible, endoscopically delivered device that mimics biliopancreatic diversion-in growing pigs. The primary aim was the superiority of ForePass over Semaglutide…
BACKGROUND/OBJECTIVE: Cystic fibrosis (CF)-related diabetes (CFRD) is a common extrapulmonary complication of CF, with increasing prevalence. As individuals with CF live longer, obesity rates are increasing, leading to an emerging phenotype called CF…
Tirzepatide, a dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like Peptide 1 (GLP-1) analogue, is a novel medication with comparable pharmacological characteristics and has demonstrated promising weight reduction outcomes in its ant…
Glucagon-like peptide-1 receptor agonist (GLP1a) agonists are one of the most recent discoveries to improve blood glucose control and provide satiety. The U.S. Food and Drug Administration (FDA) approved the first of these therapeutics for the manage…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes and obesity due to their metabolic effects. Emerging evidence suggests they may also have neuroprotective effects, indicating their potential as…
BACKGROUND: Gestational diabetes mellitus (GDM) is a widespread pregnancy complication, affecting approximately 7% to 10% of pregnancies worldwide and presenting risks for both maternal and fetal health. Traditional treatments, including lifestyle ch…